Biosimilars

March 2013 Meetings

The generic marketplace remains dynamic and complicated, as patent expirations,interest in biosimilars, and international competition spur major changes.

To get perspective on the ACA ruling's impact on specialty pharmacy, Specialty Pharmacy Times interviewed D'vorah Graeser, PhD, about the Biologics Price Competition and Innovation Act (BPCIA).

Employers are concerned with worker health behaviors and want to control spending on expensive specialty medications, according to a new survey released by Express Scripts.

Pharmacists should be knowledgeable about the different approaches used to modify biopharmaceuticals and how they affect stability, dosing, safety, and efficacy.

Payer response to new entrants to the multiple sclerosis (MS) market is mixed as some believe that there remain meaningful, major unmet needs in the MS category, according to The Zitter Group's Spring 2011 Managed Care Biologics and Injectables Index.